back to Australia directory
australia clinical guidance

Psychosis & schizophrenia: early recognition + physical health monitoring

A detailed Australian summary of psychosis & schizophrenia: early recognition + physical health monitoring, with source-attributed priorities, a practical workflow, safety escalation and state or territory implementation boundaries.

JurisdictionAustralia
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceHealthcare professionals practising in Australia
This is an iatroX educational summary of named Australia sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Apply current TGA product information, PBS restrictions, state or territory law, local referral criteria, formulary and antimicrobial policy. A national recommendation does not create uniform service access.

Scope

Assess hallucinations, delusions, thought disorder, negative symptoms and functional decline while checking substances, mood, trauma, neurological illness and delirium. A first episode needs prompt specialist assessment and coordinated early-psychosis care; avoid allowing routine investigations to delay urgent engagement. This summary is limited to the population, decisions and escalation boundaries stated in the named source.
sources for this section:ANZJP schizophrenia guideline

The Bottom Line

  • Assess hallucinations, delusions, thought disorder, negative symptoms and functional decline while checking substances, mood, trauma, neurological illness and delirium.
  • A first episode needs prompt specialist assessment and coordinated early-psychosis care; avoid allowing routine investigations to delay urgent engagement.
  • Provide family psychoeducation and relapse planning with consent and include housing, education and employment recovery goals.
  • Discuss antipsychotic choice through prior response, metabolic, neurological, prolactin, cardiac and sexual adverse effects and the person鈥檚 preferences.
sources for this section:ANZJP schizophrenia guideline

Practical clinical workflow

1

Topic-specific assessment action

Assess hallucinations, delusions, thought disorder, negative symptoms and functional decline while checking substances, mood, trauma, neurological illness and delirium.
2

Topic-specific diagnostic action

Discuss antipsychotic choice through prior response, metabolic, neurological, prolactin, cardiac and sexual adverse effects and the person鈥檚 preferences.
3

Topic-specific management action

Monitor weight, waist, blood pressure, glucose, lipids, movement disorder, smoking and physical health with named responsibility across shared care.
4

Topic-specific follow-through

Clozapine needs a registered monitoring programme and urgent assessment of fever, chest pain, constipation or myocarditis and agranulocytosis symptoms.
sources for this section:ANZJP schizophrenia guideline

Safety boundaries and escalation

  • Urgently escalate command hallucinations, severe agitation, catatonia, inability to meet basic needs, suicidality, violence risk or suspected neuroleptic malignant syndrome.
  • Offer smoking cessation while anticipating altered concentrations of smoke-metabolised antipsychotics when smoking changes.
sources for this section:ANZJP schizophrenia guideline

Implementation

The named source is national or binational guidance used in Australia, but referral access, public-health directions, formularies and funded services can still differ by state, territory and health service. Check current TGA product information for medicines. Offer culturally safe care and use the NACCHO鈥揜ACGP National Guide where Aboriginal and Torres Strait Islander preventive or chronic-care recommendations differ.
sources for this section:ANZJP schizophrenia guideline

Clinical use boundary

This independently written summary is not an official guideline. Check the linked source version, current TGA-approved product information where medicines are involved, and the applicable state, territory and local pathway at the point of care.

sources for this section:ANZJP schizophrenia guideline

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Australian and New Zealand Journal of Psychiatry guideline panelAustralian and New Zealand Journal of Psychiatry GRADE guidelines for the management of schizophreniaDOI 10.1177/00048674251406058 路 2026 GRADE guideline 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the Australia question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.